| Cas No.: | 543906-09-8 |
| 名称: | methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate |
| 别名: | UNII-GT0I9SV4F6; AFQ056; Mavoglurant; SureCN989279; GT0I9SV4F6; CHEMBL3087515; AFQ 056; AFQ-056 |
| SMILES: | N(C(OC)=O)1[C@@]([H])2[C@@]([H])([C@@](O)(C#CC3=CC=CC(C)=C3)CCC2)CC1 |
| 分子式: | C19H23NO3 |
| 分子量: | 313.39082 |
| 纯度: | |
| 保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | |
| In Vivo: | |
| In Vitro: | |
| References: | Mavoglurant (AFQ056) is an experimental drug candidate For the treatment of fragile X syndrome. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). Mavoglurant is under development by Novartis and is currently in Phas |
| Kinase Assay: | |
| Cell Assay: | |
| Animal Administration: | |
| References: |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
